BioInvent International Stock (OTC: BOVNF)

Latest news for BioInvent International (OTC:BOVNF) Stock

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

Biotech

News

Penny Stocks

Health Care

Contracts

General

BOVNF

EXEL

Exelixis-BioInvent Establish Immuno-Oncology Pact

Small Cap

Movers

Trading Ideas

CASI

Casi Pharma-Partnered BioInvent&#39;s Lead Cancer Program Gets FDA Orphan Drug Tag

BIOINVENT INTL NEW by Bioinvent International AB

BioInvent International AB

BioInvent International reports Q2 results

BioInvent International reports Q3 results

BioInvent International

<ul>
	<li>Exelixis Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) and&nbsp;BioInvent International AB&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BOVNF#OTC">BOVNF</a>) have entered into an&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/06/b27733789/exelixis-and-bioinvent-establish-exclusive-option-and-license-agreement-to-develop-novel-antibody-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">option and license agreement</a>&nbsp;focused on identifying and developing novel antibodies for use in immuno-oncology therapeutics.&nbsp;</li>
	<li>Exelixis will pay BioInvent an upfront fee of $25 million in exchange for rights to select three targets identified using BioInvent&#39;s proprietary F.I.R.S.T platform and n-CoDeR library.&nbsp;</li>
	<li>BioInvent will be responsible for initial target and antibody discovery activities and characterization of antibody mechanism of action.&nbsp;</li>
	<li>Exelixis will have the right to exercise an option to in-license any of the target programs upon identifying a development candidate directed to that target.&nbsp;</li>
	<li>Upon option exercise, Exelixis will pay BioInvent an option exercise fee. They will assume responsibility for the development candidate&#39;s future development and commercialization activities, including potential ADC and bispecific antibody engineering activities.&nbsp;</li>
	<li>In addition, BioInvent will be eligible for success-based development and commercialization milestones, as well as tiered royalties on the annual net sales.</li>
	<li>Price Action:&nbsp;EXEL shares are down 1.53% at $17.67 on the last check Thursday.</li>
</ul>

The&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/01/n25129704/casi-pharmaceuticals-partner-bioinvent-announces-bi-1206-granted-orphan-drug-designation-by-the-u-" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">FDA has granted Orphan Drug Designation</a>&nbsp;to&nbsp;BioInvent International AB&#39;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BOVNF#OTC">BOVNF</a>) BI-1206, an anti-FcyRllB antibody, for follicular lymphoma (FL) the most common form of Non-Hodgkin lymphoma (NHL).

<ul>
	<li>BioInvent is a collaborating partner of&nbsp;CASI Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>).</li>
	<li>BI-1206 is BioInvent&#39;s lead drug candidate and is currently being investigated in two Phase 1/2 trials.&nbsp;</li>
	<li>One trial is evaluating the BI-1206 combination with rituximab for Non-Hodgkin lymphoma in patients who have relapsed or are refractory to rituximab.&nbsp;</li>
	<li>A second Phase 1/2 trial is investigating BI-1206 in combination with&nbsp;Merck &amp; Co Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.</li>
	<li>Price Action:&nbsp;CASI shares are up 4.21% at $0.72&nbsp;during the premarket session on the last check Thursday.</li>
</ul>

Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag

-

-

-

-

-

-

-

-

-

-

-

-

-

-

BioInvent International

News

Latest news for BioInvent International (OTC:BOVNF) Stock

Thursday, June 16, 2022

Thursday, January 20, 2022